246 related articles for article (PubMed ID: 17455259)
1. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group.
Beckers T; Burkhardt C; Wieland H; Gimmnich P; Ciossek T; Maier T; Sanders K
Int J Cancer; 2007 Sep; 121(5):1138-48. PubMed ID: 17455259
[TBL] [Abstract][Full Text] [Related]
2. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
Long J; Zhao J; Yan Z; Liu Z; Wang N
Int J Cancer; 2009 Mar; 124(5):1235-44. PubMed ID: 19058176
[TBL] [Abstract][Full Text] [Related]
4. Differential protein acetylation induced by novel histone deacetylase inhibitors.
Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
[TBL] [Abstract][Full Text] [Related]
5. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
[TBL] [Abstract][Full Text] [Related]
6. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
Atadja P; Hsu M; Kwon P; Trogani N; Bhalla K; Remiszewski S
Novartis Found Symp; 2004; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
[TBL] [Abstract][Full Text] [Related]
7. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
10. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
Dehmel F; Weinbrenner S; Julius H; Ciossek T; Maier T; Stengel T; Fettis K; Burkhardt C; Wieland H; Beckers T
J Med Chem; 2008 Jul; 51(13):3985-4001. PubMed ID: 18558669
[TBL] [Abstract][Full Text] [Related]
11. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
Boissinot M; Inman M; Hempshall A; James SR; Gill JH; Selby P; Bowen DT; Grigg R; Cockerill PN
Leuk Res; 2012 Oct; 36(10):1304-10. PubMed ID: 22818799
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
13. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Romanski A; Bacic B; Bug G; Pfeifer H; Gul H; Remiszewski S; Hoelzer D; Atadja P; Ruthardt M; Ottmann OG
Haematologica; 2004 Apr; 89(4):419-26. PubMed ID: 15075075
[TBL] [Abstract][Full Text] [Related]
14. A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening.
Ciossek T; Julius H; Wieland H; Maier T; Beckers T
Anal Biochem; 2008 Jan; 372(1):72-81. PubMed ID: 17868634
[TBL] [Abstract][Full Text] [Related]
15. DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells.
Pont LM; Naipal K; Kloezeman JJ; Venkatesan S; van den Bent M; van Gent DC; Dirven CM; Kanaar R; Lamfers ML; Leenstra S
Cancer Lett; 2015 Jan; 356(2 Pt B):525-35. PubMed ID: 25305451
[TBL] [Abstract][Full Text] [Related]
16. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
17. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
[TBL] [Abstract][Full Text] [Related]
19. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
20. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
